NCT01827891

Brief Summary

This single-center, randomized controlled trial is to investigate the impact of remote ischemic preconditioning (RIPC) on the risk contrast-induced acute kidney injury and its long-term impact on renal function for patients with diabetes undergoing percutaneous coronary intervention.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
310

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2012

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 31, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 10, 2013

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

April 10, 2013

Status Verified

April 1, 2013

Enrollment Period

10 months

First QC Date

March 31, 2013

Last Update Submit

April 9, 2013

Conditions

Keywords

acute kidney injurypercutaneous coronary interventionremote ischemic preconditioning

Outcome Measures

Primary Outcomes (1)

  • acute kidney injury

    The primary study endpoint was AKI, defined as an absolute rise in serum creatinine of ≥ 0.5 mg/dl or a relative increase of ≥ 25% compared to baseline within 72 hours from PCI (the maximal measured concentration of serum creatinine during these 72 hours was used).

    72 hours after procedure

Secondary Outcomes (1)

  • relative reduction in estimated glomerular filtration rate

    180 days after procedure

Study Arms (2)

control group

PLACEBO COMPARATOR

Control participants did not experience the procedure of transient upper-limb ischemia.

remote ischemic preconditioning (RIPC) group

ACTIVE COMPARATOR

Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.

Procedure: remote ischemic preconditioning (RIPC)

Interventions

Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.

remote ischemic preconditioning (RIPC) group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with diabetes undergoing percutaneous coronary intervention were included.

You may not qualify if:

  • emergency PCI,
  • baseline troponin value \> 0.04 ng/mL,
  • nicorandil or glibenclamide use (preconditioning-mimetic and preconditioning-blocking medication, respectively),
  • patient on dialysis,
  • patients who had some inability to cooperate with the trial,
  • those who could not give informed consent, and (7) second procedure of staged elective PCI in this hospitalization.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Anzhen Hospital, Capital Medical University

Beijing, 100029, China

Location

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor of cardiology, Vice president of Beijing Anzhen Hospital

Study Record Dates

First Submitted

March 31, 2013

First Posted

April 10, 2013

Study Start

March 1, 2012

Primary Completion

January 1, 2013

Study Completion

June 1, 2013

Last Updated

April 10, 2013

Record last verified: 2013-04

Locations